ArticleBiochemistry and biophysics reports2025
A comprehensive risk model of disulfidoptosis-related lncRNAs predicts prognosis and therapeutic implications in bladder cancer.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disulfidoptosis is an emerging form of regulated cell death; however, the roles of its associated long non-coding RNAs (dr-lncRNAs) in bladder cancer (BLCA) remain poorly characterized. By leveraging the most comprehensive curated dataset of disulfidoptosis-related genes to date, we systematically developed and validated a novel dr-lncRNA signature that elucidates the prognostic significance and immune microenvironmental dynamics in BLCA. Methods: The Cancer Genome Atlas (TCGA) database was utilized to extract significant clinical and RNA sequencing data of BLCA patients. Cox and Lasso regression with several variables was used to create a risk model. ROC, Kaplan-Meier, and nomogram analyses were carefully reviewed for validity. The validated study evaluated intricate interactions between functional enrichment, immune cell infiltration, cancer mutation load, and treatment sensitivity. Unsupervised consensus clustering identified subgroup patterns that reflected immune system alterations, medication susceptibility, and prognosis. Results: Nine lncRNAs significantly correlated with prognosis were collectively identified, subsequently forming the basis for constructing a risk model consisting of seven lncRNAs. The model exhibited significant superiority in predicting patient outcomes, effectively distinguishing between high-risk from low-risk individuals. Functional enrichment analysis uncovered their potential involvement in immune-related biological pathways. Patients in the high-risk group exhibited higher tumor mutation burdens, more active immune functions and a higher sensitivity to chemotherapeutic drugs. Variations among BLCA subgroups were identified by consensus cluster analysis, including clinical characteristics, prognosis, lncRNA expression, immune cell infiltration, and immune checkpoint profiles. Conclusion: The dr-lncRNAs-based risk model presents a promising tool for predicting prognosis and guiding personalized immunotherapy and treatment strategies in BLCA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.